Table 2.
Clinical characteristics and lab tests at the time of COVID-19 diagnosis and survival
| Variables | Recovered (n = 94) | Non-survivors (n = 33) | P-value |
|---|---|---|---|
| Donor type (DBD/cDCD/LD), n/n/n | 54/29/11 | 19/14/0 | .089 |
| Donor age (years), mean (SD) | 57.5 (14.6) | 68.0 (8.6) | .000 |
| Donor sex (male/female), n/n | 51/41 | 20/12 | .487 |
| Patient age (years), mean (SD) | 56.1 (13.9) | 66.7 (18.7) | .000 |
| Patient age >65 years (yes/no), n/n | 26/68 | 25/8 | .000 |
| Patient sex (male/female), n/n | 56/38 | 21/12 | .681 |
| Arterial hypertension (yes/no), n/n | 79/15 | 31/2 | .151 |
| Diabetes (yes/no), n/n | 28/66 | 20/13 | .002 |
| BMI >30 kg/m2 (yes/no), n/n | 15/78 | 14/19 | .002 |
| Previous cancer (yes/no), n/n | 13/81 | 9/24 | .079 |
| Pneumopathy (yes/no), n/n | 13/81 | 7/26 | .317 |
| Retransplant (yes/no), n/n | 11/83 | 8/25 | .082 |
| cPRA (%), mean (SD) | 14.7 (31.0) | 24.2 (36.3) | .076 |
| HLA mismatch, n (%) | 4.0 (2.5) | 3.6 (1.8) | .845 |
| Induction therapy (basiliximab/ATG), n/n | 54/40 | 19/14 | .990 |
| Maintenance immunosuppression (TAC + MMF + P/TAC + mTOR-i + P), n/n | 80/14 | 32/1 | .069 |
| DGF (yes/no), n/n | 26/68 | 19/14 | .002 |
| Acute rejection (yes/no), n/n | 7/87 | 34/0 | .188 |
| Transplant to COVID-19 diagnosis time (months), mean (SD) | 3.0 (3.3) | 2.2 (2.0) | .915 |
| Hospitalization (yes/no), n/n | 74/20 | 33/0 | .004 |
| Nosocomial infection (yes/no), n/n | 37/56 | 19/14 | .077 |
| ARDS (yes/no), n/n | 11/83 | 29/4 | .000 |
| ICU admission (yes/no), n/n | 14/80 | 15/18 | .000 |
| Invasive mechanical ventilation (yes/no), n/n | 8/86 | 14/19 | .000 |
| AKI (yes/no), n/n | 33/56 | 21/10 | .003 |
| Haemodialysis requirement (yes/no), n/n | 10/81 | 18/15 | .000 |
| Lab tests at diagnosis of COVID-19, mean (SD) | |||
| Creatinine (mg/dL) | 2.1 (1.5) | 3.6 (2.4) | .011 |
| Lymphocytes (×109/L) | 510 (386) | 479 (377) | .653 |
| D-dimer (ng/mL) | 1581 (1627) | 4247 (7169) | .007 |
| Interleukin-6 (pg/mL) | 49 (62) | 227 (390) | .002 |
| C-reactive protein (mg/dL) | 17 (30) | 41 (53) | .002 |
Comparison between groups was performed using Pearson's chi-squared test for categorical data and t-tests for continuous normally distributed data. Statistically significant values are in bold.
DBD, donation after brain death; cDCD, controlled donation after circulatory death; LD, living donation; TAC, tacrolimus; MMF, mycophenolate; P, prednisone.